This article is more than 5 years old. Information may no longer be current.
Allergan, Molecular Partners enter exclusive license agreement for MP0112
Click Here to Manage Email Alerts
ZURICH-SCHLIEREN, Switzerland — Allergan and Molecular Partners announced that they have entered into a license agreement for the protein MP0112, according to a press release from Molecular Partners.
The announcement was made in conjunction with the release of data from two separate phase 1/2a trials for MP0112 presented at the Association for Research in Vision and Ophthalmology meeting.
The agreement gives Allergan exclusive global rights for MP0112 for ophthalmic indications. MP0112 is a phase 2 proprietary therapeutic DARPin protein targeting VEGF, and it is currently under investigation for the treatment of retinal diseases.
Compensation includes an upfront payment of $45 million to Molecular Partners, which is further entitled to $375 million in additional payments upon meeting certain development, regulatory and sales milestones. Molecular Partners will also receive tiered double-digit royalties on any future sales of MP0112, the release said.
"The goal of this program is to develop a potentially more effective treatment for diseases like neovascular age-related macular degeneration with the possibility for less frequent intravitreal injections," Scott M. Whitcup, MD, Allergan's executive vice president of research and development and chief scientific officer, said in the release.
The companies will work together during phase 2b development, with Allergan taking the lead on phase 3 development and commercialization.